Next generation anti-inflammatory drugs
EPAC1: The Holy Grail Target In Inflammatory Disorders
We are a team of experienced innovators with a passionate belief that current treatment for inflammatory disorders is not good enough.
Through our research, we have developed an approach to treat what we think is the most exciting new target in inflammation.
Treating the silent epidemic of inflammation is what we think about 24/7 and we will not rest until patients get the treatment options they deserve.
Small molecule EPAC activators
Audax’ compounds have exhibited broad anti-inflammatory effects in vitro, by their highly specific targeting of EPAC1
Almost every common chronic disease has an inflammatory component
Much of the inflammatory activity is associated with over activity of IL-6 (interleukin 6)
IL-6 activity can be suppressed by the enzyme EPAC1
Our current focus is inflammation and fibrosis in pulmonary tissues
Future applications are likely to include vascular inflammation and ocular fibrosis
The company is focussed on developing inhaled compounds targeting pulmonary fibrosis